EUVIMEDEUVIMED entdecken
Crossref

Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma

Shohei Komatsu, Yoshihiko Yano, Takuya Mimura, Akihiro Minami, Kenji Momose, Hirotaka Hirano, Motofumi Tanaka, Yuki Ueda, Kentaro Tai, Yuki Yasuhara, Daisuke Nakagawa, Atsushi Yamamoto und 4 weitere

Anticancer Research · 2024

DOI: 10.21873/anticanres.17123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Shohei Komatsu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; komasho8@med.kobe-u.a…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Quinolines, Phenylurea Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Sorafenib and lenvatinib have long been used as a first-line treatment for advanced hepatocellular carcinoma (HCC). Along with the development of systemic chemotherapy for HCC, the concept of conversion hepatectomy has recently become widespread. The present study aimed to assess the clinical outcomes of sorafenib and lenvatinib for HCC regarding the possibility of conversion hepatectomy in clinical practice. PATIENTS AND METHODS: A total of 295 patients with advanced HCC receiving sorafenib and lenvatinib, accounting for 306 treatments (sorafenib, n=157; lenvatinib, n=149, 11 patients received lenvatinib after sorafenib treatment) at five different institutions were enrolled. Patients were assessed for their clinical characteristics and therapeutic response using both Response Evaluation Criteria in Solid Tumors criteria (RECIST) and modified RECIST (mRECIST) criteria. Additionally, an indication of surgery after tyrosine kinase inhibitor administration was determined based on the tumor status of patients. RESULTS: The median survival times of patients treated with sorafenib and lenvatinib were 12.8 and 16.4 months, respectively, without significant difference (p=0.1645). The objective response rates (ORR) of sorafenib based on mRECIST and RECIST were 10.1% and 5.9%, respectively, and those of lenvatinib were 38.1% and 19.0%, respectively. Among the 306 treatments, two cases (sorafenib and lenvatinib, one each) underwent hepatectomy after systemic chemotherapy. CONCLUSION: Few cases with unresectable HCC were amenable to conversion hepatectomy after sorafenib and lenvatinib treatments due to the limited ORR by RECIST. Cautious approach must be taken when administering neoadjuvant chemotherapy aimed at conversion hepatectomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsQuinolinesPhenylurea CompoundsSorafenibHepatectomyHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents

Stichwörter der Autor:innen

Hepatocellular carcinomaLenvatinibRECISTSorafenibmRECIST

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsSorafenibAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; komasho8@med.kobe-u.ac.jp.
  • Department of Internal Medicine, Division of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Gastroenterology, Kakogawa Central City Hospital, Hyogo, Japan.
  • Department of Gastroenterology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
  • Department of Gastroenterology, Yodogawa Christian Hospital, Osaka, Japan.
  • Department of Gastroenterological Surgery, Hyogo Cancer Center, Hyogo, Japan.

Zitieren

APA

Komatsu, S., Yano, Y., Mimura, T., Minami, A., Momose, K., Hirano, H., Tanaka, M., Ueda, Y., Tai, K., Yasuhara, Y., Nakagawa, D., Yamamoto, A., Kido, M., Ueda, Y., Kodama, Y., & Fukumoto, T. (2024). Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.17123

Vancouver

Komatsu S, Yano Y, Mimura T, Minami A, Momose K, Hirano H, et al. Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. Anticancer Research. 2024. doi:10.21873/anticanres.17123

BibTeX
@article{Komatsu2024,
  author = {Komatsu, Shohei and Yano, Yoshihiko and Mimura, Takuya and Minami, Akihiro and Momose, Kenji and Hirano, Hirotaka and Tanaka, Motofumi and Ueda, Yuki and Tai, Kentaro and Yasuhara, Yuki and Nakagawa, Daisuke and Yamamoto, Atsushi and Kido, Masahiro and Ueda, Yoshihide and Kodama, Yuzo and Fukumoto, Takumi},
  title = {Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.17123}
}
Kostenlos starten →